All companies › LGND

LGND · LIGAND PHARMACEUTICALS INC

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells5
Research cases0
Last filing2026-09-03

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-03 — Reardon Andrew · sold 300 @ $283.99 2026-09-03 — Reardon Andrew · sold 1,800 @ $285.17 2026-09-03 — Reardon Andrew · sold 2,115 @ $286.36 2026-09-03 — Reardon Andrew · sold 385 @ $287.53 2026-09-03 — Reardon Andrew · sold 400 @ $288.98
2026-09-032026-09-03

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Reardon Andrew CLO & Secretary
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $LGND is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-03', 'insider_name': 'Reardon Andrew', 'insider_title': 'CLO & Secretary', 'transaction_type': 'Open-market sell', 'shares': 300.0, 'price': 283.9854, 'value': 85195.62, 'is_buy': False}, {'transaction_date': '2026-09-03', 'insider_name': 'Reardon Andrew', 'insider_title': 'CLO & Secretary', 'transaction_type': 'Open-market sell', 'shares': 1800.0, 'price': 285.1671, 'value': 513300.78, 'is_buy': False}, {'transaction_date': '2026-09-03', 'insider_name': 'Reardon Andrew', 'insider_title': 'CLO & Secretary', 'transaction_type': 'Open-market sell', 'shares': 2115.0, 'price': 286.3589, 'value': 605649.07, 'is_buy': False}, {'transaction_date': '2026-09-03', 'insider_name': 'Reardon Andrew', 'insider_title': 'CLO & Secretary', 'transaction_type': 'Open-market sell', 'shares': 385.0, 'price': 287.5253, 'value': 110697.24, 'is_buy': False}, {'transaction_date': '2026-09-03', 'insider_name': 'Reardon Andrew', 'insider_title': 'CLO & Secretary', 'transaction_type': 'Open-market sell', 'shares': 400.0, 'price': 288.9792, 'value': 115591.68, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for LGND today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.